ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACXP vs SCNX // PIOTROSKI F-SCORE QUALITY

Acurx Pharmaceuticals Inc. (NASDAQ) VS. Scienture Holdings Inc. (NASDAQ) • 15-METRIC TALLY: ACXP 1 — SCNX 2
▲ PIOTROSKI F-SCORE QUALITY LEADER: SCNX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACXP VS. SCNX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACXP SCNX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 76.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 2/9 4/9 -2.00 SCNX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 26.6 32.0 -5.37 SCNX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.9M $5.7M $216.0K ACXP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACXP REV SCNX REV ACXP GROSS % SCNX GROSS % ACXP FCF SCNX FCF
FY 2025 $0 $431.6K — 76.8% -$6.8M -$13.4M
FY 2024 $0 $136.6K — 4.4% -$10.4M -$14.3M
FY 2023 $0 $1.4M — — -$9.8M -$2.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACXP // BETA —
SCNX // BETA —